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Primary hyperparathyroidism (PHPT) is a disorder
caused by excessive secretion of parathormone by one or
more
enlarged
parathyroid
glands.
Primary
hyperparathyroidism has become a common disease,
affecting an estimated 28 per 100,000 people in the
United States. There have been significant changes in the
understanding of the disease process and advances in the
management of PHPT in the last decade. The increased
recognition of PHPT due to the more widespread use of
screening tests resulted in a new clinical profile of
hyperparathyroidism,
characterized
by
mild
hypercalcemia with absent or subtle symptoms.
Consequently, the number of parathyroidectomies
performed for PHPT has also increased worldwide.
Minimally invasive parathyroidectomy (MIP) has replaced
the traditional 4 gland exploration as the procedure of
choice in many institutions, with comparable cure rates
(1,2).
The goal of surgery for PHPT is to return the
patient’s calcium level to normal. This should be
accomplished with minimal morbidity, no mortality and
low recurrence rates, at a reasonable cost.
The standard parathyroidectomy was first performed
in 1925 with bilateral neck exploration, and it has
remained the standard treatment of PHPT (3). In this
standard approach, when one gland is determined to be
grossly enlarged, excision of this abnormal parathyroid is
performed with or without biopsy of the remaining
glands. When more than one gland is enlarged, the
operative techniques include a 31/2-gland resection
(leaving approximately 50-100mg of the most “normal-

appearing” gland), excising only those glands that are
grossly enlarged at the exploration, and less commonly a
4-gland
parathyroidectomy
with
subsequent
autotransplantation. Success with this approach as
measured by return to normal calcium levels depends
primarily on the experience and judgment of the surgeon
in recognizing the difference between enlarged and
normal sized glands. Although the size of the parathyroid
gland does not always correlate well with the secretion of
the parathyroid hormone, and may be problematic, in
expert hands the cure rate of standard 4 gland
exploration parathyroidectomy is over 95%, even with 4
gland hyperplasia (4,5).
The success of surgical treatment depends on success
in the localization and identification of abnormal glands.
Difficulties associated with parathyroidectomy for PHPT
relate to the variability in the number of parathyroid
glands, the different locations of normal and abnormal
glands, and problems distinguishing normal glands from
those that are subtly diseased.
The surgical anatomy of parathyroid glands is intricate
and variable. In most cases, normal upper glands are
located in the posterior to the middle and upper third of
the thyroid lobe and posterior to the recurrent laryngeal
nerves. The location of normal inferior parathyroid
glands, however, is more variable. In approximately 50%
of explorations they are found posteriorly or laterally to
the lower pole of the thyroid lobe. With decreasing
frequency, they are found within the thyrothymic
ligament and the thymus in the mediastinum or are
intrathyroidal. When parathyroid glands become
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adenomatous/hyperplastic and enlarge, their location
may change somewhat. Although 80% to 85% of
parathyroid adenomas are found adjacent to the thyroid
gland in their normal location, 15% to 20% are
ectopically placed. Ectopic abnormal glands may be found
in the anterior-superior mediastinum, either within or
outside the thymus, along the esophagus into the
posterior-superior mediastinum, or very rarely in the
middle mediastinum. Occasionally, they may be found
within or even lateral to the carotid sheath. Rarely, an
undescended lower parathyroid gland is found high in the
neck, anterior to the carotid bifurcation. Finally, 3% to
5% of all parathyroid adenomas are intrathyroidal,
usually within the lower pole of the thyroid gland.
Approximately 85% of individuals have 4 glands, 5%
have 5, and 10% have 3 glands identified. The variability
in the number of glands may lead to situations in which a
patient has 4 normal glands in the neck and an abnormal
fifth one located in the mediastinum (6,7).
Another challenging aspect of parathyroid surgery is
to distinguish an adenoma from hyperplasia. This
distinction is not only difficult intraoperatively, but
histopathologically as well. The histopathologic criteria
used to distinguish adenoma from hyperplasia are not
well defined. Current facts regarding the
histopathogenesis of parathyroid adenoma and
hyperplasia are also not conclusive. Most adenomas are
monoclonal proliferations suggesting a neoplastic origin.
However, there is histopathologic and cytogenetic
evidence suggesting evolution to a monoclonal adenoma
from polyclonal hyperplasia and vice versa (8).
Parathyroid adenoma and hyperplasia could well be the
same disease entity, representing opposite ends of the
spectrum of phenotypic expression. To avoid confusion
and speculations, we prefer to use the term “adenoma”
interchangeably with “single gland disease”, and
“hyperplasia” interchangeably with “multigland disease”.
Multiple endocrine neoplasia and the familial
hyperparathyroidism syndromes are associated with
multigland disease as a rule. In sporadic cases, classically,
single gland involvement (adenoma) is observed in
approximately 80% to 85% of cases, and hyperplasia is
seen in 15% to 20% of cases. In general most
experienced surgeons think that by evaluating the size,
shape and color of the parathyroid glands at operation,
they can distinguish normal glands from abnormal ones.
If one gland is enlarged and the others are perfectly
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normal, visually the diagnosis is an adenoma. Some
surgeons attempt to confirm this with a frozen section of
a biopsy from a normal gland. Hyperplasia (multigland
disease) should result in enlargement of all 4 glands.
However, asymptomatic hyperplasia may appear with 1
or 2 normal sized glands confusing the diagnosis even
when a biopsy is used. The prevalence of hyperplasia
varies considerably in different series. There appears to
be a strong influence of clinical (surgical) diagnosis on the
pathologist’s diagnosis. When subtotal parathyroidectomy
is performed, more hyperplasia is diagnosed. When a
focused operation is performed with removal of a single
gland, it is likely to be called an adenoma. The importance
of mild hyperplasia and the best way of diagnosing this
condition are yet to be determined.
The radiologic localization of abnormal parathyroid
glands has also been extremely challenging. Ultrasound
imaging has a localization accuracy of 70-80% in
unoperated patients. However, this falls to 40% in
patients who have had prior failed surgical exploration.
The sensitivity of CT scans ranges from 45% to 75%,
being lower in reoperated patients. MRI sensitivity is
similar to that of CT scans, with slightly better (50-80%)
accuracy in reoperative cases (9). The less than optimal
sensitivity of these diagnostic imaging modalities
supported the rationale for traditional neck exploration.
The NIH consensus statement on the treatment of PHPT
in 1990 stated that preoperative localization in patients
without prior neck surgery was rarely indicated and not
proven to be cost-effective. The surgeon should localize
the glands by direct visualization intraoperatively (10).
99m

In 1989, Coakley et al. incidentally noted that Tc
sestamibi exhibited uptake and retention in abnormal
201
- Tc99m
parathyroid glands. Prior to this, the Tl
pertechnetate substraction scan was being used with no
better yield than other conventional imaging techniques
(11,12). Shortly after this original report, many
investigators reported the successful localization of
abnormal parathyroid glands in patients with PHPT.
Sestamibi imaging drastically affected the management of
patients with PHPT in a remarkably short period of time.
A number of studies reported the successful utilization of
sestamibi imaging in abnormal gland localization (13,14).
Sestamibi localization in adenomatous parathyroid cells
has been shown to be in the mitochondria, and uptake is
a function of blood flow, gland size and mitochondrial
activity (15,16). The differential retention of sestamibi
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relative to thyroid tissue, however, has been shown to be
a function of p-glycoprotein down-regulation, which acts
as an out-flux carrier molecule in the parathyroid tissue
(17,18).
High quality scans accurately locate parathyroid
adenomas in 75-85% of patients with PHPT. The utility
of sestamibi imaging is markedly improved with SPECT.
The precision of localization of difficult ectopic sites, such
as retroesophageal space or mediastinum, is only possible
with high quality SPECT acquisition and interpretation
(19,20).
With the introduction of sestamibi localization, and
the identification of parathyroid adenoma location, the
era of focused exploration or minimally invasive
parathyroidectomy began. The different techniques
associated
with
focused/minimally
invasive
parathyroidectomy include gamma probe-guided
exploration, and novel endoscopic techniques. The
sophisticated techniques of parathyroid imaging allow the
surgeon to plan a localized exploration designed to
remove the common single focus of disease. The incision
is small, dissection is minimal, postoperative pain is less,
and hospital stay is shorter.
The use of an intraoperative gamma probe facilitates
the surgical exploration. The operation could be
performed through a smaller incision. The surgeon can
locate the abnormal gland readily in the direction of the
probe tip where a hot spot is identified. The identification
of the parathyroid adenoma is more challenging than it is
for sentinel node localization. Background activity in the
thyroid gland is significant and the target to background
activity ratio is variable depending on both the thyroid
and parathyroid washout rates of sestamibi. The gamma
probe is only helpful when there is a statistically
significant differential between the thyroid and
parathyroid count rates. This differential usually occurs
within a window 1.5 to 3 after the sestamibi injection.
Within this window, the ex-vivo count rate of an adenoma
is at least 20%, and is usually higher than 50%, of the
thyroid background. Selection of a gamma probe with
good directionality and scatter suppression electronics is
important for improving detection success. Ex-vivo
activity has also proven to be 100% accurate in
distinguishing parathyroid tissue from fat and lymph
nodes when the excised tissue emits 20% of the
background activity. This has been extremely useful in
reducing the need for a frozen section to identify

parathyroid tissue (21). The use of sophisticated
protocols calculating the maximum parathyroid to thyroid
uptake ratio, thus the optimal time to surgery, increases
the success of gamma probe-guided parathyroidectomy
(22).
The cost-effectiveness of the image-guided minimally
invasive approach, i.e. the expense of imaging with the
equipment required, has been questioned. However, the
potential savings from decreased operating time and
hospital stay were found to be comparable to in favor of
minimally invasive approach in many analyses (23,24). A
major concern when using a sestamibi-guided focused
unilateral surgical approach is a possible failure to
diagnose multigland disease. A recent review
demonstrated that the reported incidence of multigland
disease in series in which bilateral explorations were
performed is 20%, whereas the incidence with focused
unilateral explorations is only 5% (25). The difference
could be explained by the lower sensitivity of sestamibi
localization in multigland disease resulting in
underdiagnosis of this occurrence. However, the
possibility of overdiagnosis of multiglandular disease with
a bilateral approach (biased pathology) cannot be
discarded. The evidence-based support for minimally
invasive parathyroidectomy comes from the fact that the
recurrence rates following focused unilateral approaches
have not been higher than those of the bilateral approach.
Another change in the management of PHPT has been
the introduction of the rapid intraoperative parathyroid
hormone assay. The assay, originally reported by
Nussbaum, was refined and clinically popularized by Irwin
(26,27). This assay measures intact PTH levels in the
patient’s plasma utilizing an immunochemiluminometric
technique and can be performed during the operation.
The intact PTH has a half-life of 2 to 3 min. Therefore 5
to 10 min after the removal of the abnormal gland a
significant drop in PTH level is observed. A fall in the PTH
level greater than 50% of the preoperative level is
considered indicative of successful removal. The QPTH
has a sensitivity and specificity of 98% and 94%,
respectively, and an overall accuracy of 97% (28).
A recent survey of the members of the International
Association of Endocrine Surgeons indicated that
sestamibi-based minimally invasive parathyroidectomy
has been adapted by 59% of surgeons. The most popular
surgical technique (92%) is the focused approach with a
small incision, followed by a video-assisted technique
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(22%), and a true endoscopic technique with gas
insufflation (12%). Techniques used to ensure
completeness of resection include the QPTH (68%), and
gamma probe (14%) (29).
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